Managing clinical conditions: Chalazion and preseptal cellulitis

Article

Philadelphia-Paul Karpecki, OD, FAAO, and Jill Autry, OD, RPh, shared chalazion and preseptal cellulitis management pearls with attendees at the American Optometric Association’s Optometry’s Meeting.

 

Philadelphia-Paul Karpecki, OD, FAAO, and Jill Autry, OD, RPh, shared clinical management pearls with attendees at the American Optometric Association’s Optometry’s Meeting.

Consider steroid or injection in treatment of chalazion.

“The pressing down on the cornea sometimes becomes the main reason we remove chalazia,” says Dr. Karpecki.

“With more ophthalmologists in the office, I would do more injections,” says Dr. Autry. “About 50 percent of the time, they would do fine. In general, patients are more happy to try this route than surgery. Permanent discoloration may be a concern in patients of color.”

Preseptal cellulitis often follows acute hordeolum

With children undergoing treatment for conjunctivitis, be careful of a red sheen around the eye. It's an early sign of preseptal cellulitis with H. influenzae. “Any reddish sheen is enough to continue treating systemically with oral medications and take a temperature.ODT

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.